RxDoctor Payments Data

Tara Trenhaile

Physician Assistant · Fort Myers, FLNPI 1821614991

Payments from drug & device makers

$2,865in general payments, 2019–2025

Across 140 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$647
  • Tandem Diabetes Care, Inc.$295
  • Dexcom, Inc.$261
  • Lilly USA, LLC$180
  • Amgen$179
  • AbbVie$172
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,865100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,865 in reported general payments places this provider in the 80th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$11,257
Medicare patients
182
Services billed
353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide297$538,000
JardianceEmpagliflozin263$427,850
TrulicityDulaglutide213$383,056
MounjaroTirzepatide156$262,442
Tresiba Flextouch U-200Insulin Degludec168$206,655
Fiasp FlextouchInsulin Aspart (Niacinamide)65$99,273
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/763$92,538
JanuviaSitagliptin Phosphate56$80,320
ForteoTeriparatide19$78,821
Humulin R U-500 KwikpenInsulin Regular, Human32$76,334
Lantus SolostarInsulin Glargine,hum.Rec.Anlog333$67,509
FarxigaDapagliflozin Propanediol51$56,377
Tresiba Flextouch U-100Insulin Degludec62$52,206
RybelsusSemaglutide21$46,595
ProliaDenosumab26$42,870

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Forteo, Humalog, Insulin Lispro$180$746,714467 claims
Novo NordiskOzempic, Rybelsus, Novolog$647$598,735346 claims
Boehringer IngelheimJardiance, Tradjenta$129$453,985292 claims
AmgenProlia$179$42,87026 claims
Sanofi-aventis U.S. LLCLantus$135$17,84954 claims
AbbVieSynthroid$172$4,90964 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →